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Abstract
Background—Few epidemiologic studies have investigated the use of venlafaxine (Effexor®), 
an antidepressant used to treat major depression and anxiety disorders in adults, during pregnancy. 
Our objective was to determine whether use of venlafaxine during pregnancy is associated with 
specific birth defects.
Methods—We used data from the National Birth Defects Prevention Study (NBDPS), a 
population-based, case-control study in the United States. Our analysis included mothers with 
pregnancies affected by one of 30 selected birth defects (cases) and babies without birth defects 
(controls) with estimated dates of delivery between 1997–2007. Exposure was any reported use of 
venlafaxine from one month preconception through the third month of pregnancy. We calculated 
adjusted odds ratios (aORs) and 95% Fisher’s Exact confidence intervals (CIs) for 24 birth defect 
groups for which at least 400 case mothers were interviewed. Our adjusted analyses controlled for 
maternal age and race-ethnicity.
Results—Among the 27,045 NBDPS participants who met inclusion criteria, 0.17% (14/8,002) 
of control mothers and 0.40% (77/19,043) of case mothers reported any use of venlafaxine from 
one month preconception through the third month of pregnancy. Statistically significant 
associations were found for anencephaly, atrial septal defect (ASD) secundum or ASD not 
otherwise specified, coarctation of the aorta, cleft palate, and gastroschisis.
Conclusions—Our data suggest associations between periconceptional use of venlafaxine and 
some birth defects. However, sample sizes were small, confidence intervals were wide, and 
additional studies are needed to confirm these results.
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Introduction
Venlafaxine (Effexor®) is a medication that is used to treat major depressive, generalized 
anxiety and social anxiety disorders in adults. The prevalence of depression during 
pregnancy is about 18% and the prevalence of generalized anxiety disorders is estimated to 
be 8.5% among pregnant women (Ross and McLean, 2006; Yonkers and others, 2009). 
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI), which functions to 
block the reuptake of both serotonin and norepinephrine, and at high doses, also may affect 
reuptake of dopamine (Sussman, 2003). The mechanism of action for SNRIs is similar to 
another common class of antidepressants, selective-serotonin reuptake inhibitors (SSRIs), 
which act to block the reuptake of serotonin alone (Sussman, 2003).
Few epidemiologic studies have investigated the use of venlafaxine during pregnancy and 
birth defects. Because of small numbers, some studies have grouped exposure to venlafaxine 
with exposure to SSRIs (citalopram, fluoxetine, paroxetine, and sertraline) or other newer 
antidepressants, which does not allow for examination of specific effects of venlafaxine 
exposure separate from these other antidepressant medications (Einarson and others, 2009; 
Ferreira and others, 2007; Kallen, 2004b; Lennestal and Kallen, 2007; Reis and Kallen, 
2010; Wichman and others, 2009; Yaris and others, 2004). In general, these studies found no 
associations between major malformations and SNRI medications as a group. Of those who 
assessed venlafaxine separately, no significant associations were observed. For example, a 
study by Einarson and colleagues found no significant differences in the prevalence of birth 
defects between women who were exposed to venlafaxine and women exposed to SSRIs or 
medications believed to be non-teratogenic during pregnancy (n=150 per group) (Einarson 
and others, 2001; Oberlander and others, 2008). Similarly, Oberlander and colleagues used 
administrative health data to look at serotonin reuptake inhibitors including venlafaxine, 
individually and as a group, and found no increased risk for birth defects overall or 
specifically for cardiac defects when compared to women unexposed to SSRIs, SNRIs, and 
benzodiazepines (Oberlander and others, 2008).
Several studies have examined the associations between use of SSRIs during pregnancy and 
birth defects and have reported mixed results. Some suggest that SSRIs might be associated 
with an increased risk of heart defects, mainly septal defects and right ventricular outflow 
tract obstruction (RVOTO) defects (Bar-Oz and others, 2007; Berard and others, 2007; Cole 
and others, 2007; Diav-Citrin and others, 2008; Einarson and others, 2008; Ferreira and 
others, 2007; Kallen, 2004a; Kallen and Otterblad Olausson, 2007; Louik and others, 2007). 
A previous analysis of data from the National Birth Defects Prevention Study (NBDPS) 
showed associations between SSRIs and anencephaly, craniosynostosis, and omphalocele 
(Alwan and others, 2007). A similar study by Louik and colleagues found associations 
between individual SSRIs and certain birth defects, such as sertraline and septal heart 
defects, sertraline and omphalocele, and paroxetine and right ventricular outflow tract 
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obstruction defects (Louik and others, 2007). Although SSRIs and SNRIs might function 
similarly to treat depressive symptoms, much less is known about the risk of SNRIs (such as 
venlafaxine) and their use during pregnancy.
We used data from the NBDPS to assess whether reported use of venlafaxine just before and 
during early pregnancy is associated with specific birth defects.
Methods
Study Population
The NBDPS is an ongoing, population-based, case-control study designed to investigate 
genetic and environmental risk factors for major structural birth defects (Rasmussen and 
others, 2003; Yoon and others, 2001). Birth defects data are collected by ten birth defects 
surveillance systems in the United States: Arkansas (statewide), California (region near 
Fresno), Georgia (metropolitan Atlanta), Iowa (statewide), Massachusetts (eastern counties), 
New Jersey (statewide, ending in 2002), New York (western NY and Hudson Valley), North 
Carolina (19 central counties, beginning in 2003), Texas (varying regions, currently Health 
Service Region 11), and Utah (statewide, beginning in 2003). The study was approved by 
institutional review boards of the Centers for Disease Control and Prevention and all study 
centers.
Cases include live births, stillbirths (≥20 weeks gestation), and elective terminations 
diagnosed with one of more than 30 selected major birth defects. To focus on birth defects 
of unknown etiology, infants with recognized or strongly suspected chromosomal 
abnormalities or single-gene disorders are excluded. Control infants are liveborn infants 
without birth defects randomly selected from hospital birth records or birth certificate 
records from the same source population and time period as the case infants. To confirm 
study eligibility, all case records are reviewed by clinical geneticists to determine if they 
meet the standard case definitions. Clinical information on infants with heart defects also are 
reviewed by clinicians with expertise in pediatric cardiology. All heart defect diagnoses are 
confirmed using reports from echocardiography, cardiac catheterization, surgery, or autopsy 
(Yoon and others, 2001).
Mothers of case and control infants are contacted within 6 weeks to 24 months after the 
estimated date of delivery (EDD). If the mother agrees to participate in the study, a trained 
interviewer administers a standardized computer-assisted telephone interview in English or 
Spanish. The interview ascertains specific exposures and behaviors throughout pregnancy 
and the three months preconception. During the interview, mothers are asked about maternal 
and paternal demographic characteristics, pregnancy history, medication and vitamin use, 
dietary details, drug and alcohol use, occupational exposures, and reproductive health 
information.
Venlafaxine Exposure
Exposure was defined as any reported use of venlafaxine from one month before conception 
through the third month of pregnancy (periconceptional). This exposure definition does 
include timing outside of organogenesis; however, because it is possible that women may 
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not recall dates exactly correctly (of pregnancy or of timing of the medication use), we 
included a broader time frame. During the medication portion of the NBDPS interview, 
mothers are asked about prescription and non-prescription medications that they may have 
taken from 3 months before conception through delivery. Interviewers read a list of brand 
name medications (e.g., Prozac®, Zoloft®) to the mothers, and after each medication is 
read, mothers respond yes or no to report if they had taken the medication. At the end of the 
list, they are asked if they had taken any medications that were not mentioned. For births 
with an EDD during 1997–2005, venlafaxine (Effexor®) was not one of the specific 
medications listed. In 2005, the interview was revised, and Effexor® (the more commonly 
recognized brand name for venlafaxine) was added to the list of medications that were read. 
Thus, for births with an EDD during 2006–2007, mothers responded yes or no when they 
heard venlafaxine listed. In addition, during the maternal health portion of the NBDPS 
interview, mothers are asked open-ended questions about illnesses or diseases they may 
have had during pregnancy and about any medications used for this illness. Regardless of 
where in the interview the mother reported use of a specific medication, subsequent 
questions were asked regarding start date, stop date, and frequency of use. If a mother 
reported any brand (Effexor®) or generic (venlafaxine) name for venlafaxine and reported 
periconceptional use of the antidepressant, they were classified as exposed.
Statistical Analysis
These analyses were limited to mothers who had an EDD after October 1, 1997 through 
December 31, 2007. We excluded mothers who did not complete the maternal interview 
through all of the medication questions and included only those birth defect groups for 
which there were at least 400 case mothers interviewed. Due to the strong association 
observed between pre-pregnancy diabetes and birth defects, we excluded mothers who 
reported pre-pregnancy type 1 or type 2 diabetes (Correa and others, 2008). To assess effects 
of venlafaxine separate from other antidepressants, mothers who reported other 
periconceptional antidepressant use were excluded. Lastly, we excluded mothers who had 
missing information on the timing of exposure during pregnancy or who were exposed to 
venlafaxine outside the periconceptional window of interest (Figure 1). Women were 
classified as unexposed if they did not report use of any antidepressant from three months 
before conception through the end of pregnancy.
To examine the association between exposure to venlafaxine and the occurrence of birth 
defects, we estimated crude and adjusted odds ratios (ORs) and 95% Fisher’s Exact 
confidence intervals (CIs) if there were more than 2 exposed cases. Because of the small 
number of exposed mothers, we controlled for only two variables chosen a priori: maternal 
age (<30, ≥30 years) and race/ethnicity (non-Hispanic white, other). Because gastroschisis is 
associated with young maternal age, the association with gastroschisis was adjusted for 
maternal age (<20, ≥20 years) and race/ethnicity (non-Hispanic white, other). These factors 
were self-reported during the maternal interview. Birth defect groups are not mutually 
exclusive; case infants with more than one birth defect are included in more than one 
category. Therefore, we conducted a sub-analysis restricted to cases with isolated birth 
defects, estimating crude ORs (cORs) because of decreased sample size.
Polen et al. Page 4













After reviewing preliminary results, post-hoc analyses were performed to further understand 
observed associations. Fewer case and control mothers with EDDs from 1997–2002 reported 
using venlafaxine. Therefore, we conducted sub-analyses limiting the data to the most recent 
5-year time period (EDD: 2003–2007), estimating cORs and 95% Fisher’s Exact CIs. We 
also examined other medications reported and other illnesses or diseases reported by 
venlafaxine-exposed mothers. To explore the role of recall bias, we estimated cORs under 
the assumption that, among controls only, 30% of exposed mothers erroneously had not 
reported exposure. In this hypothetical scenario, we assumed that 20 control mothers were 
truly exposed; therefore, in addition to the 14 control mothers who reported exposure, six 
more mothers were actually exposed but failed to report it (6/20=30%). We calculated 
hypothetical cORs under these assumptions to assess the effect of potential under-reporting 
among control mothers.
All statistical analyses were performed using SAS 9.3 (SAS Institute Inc, Cary, NC).
Results
Among mothers who met our inclusion criteria, 0.17% (14/8,002) of control mothers and 
0.40% (77/19,043) of case mothers reported any periconceptional use of venlafaxine. 
Duration of use ranged from 1–120 days, but the majority (54%) of mothers reported using 
venlafaxine for the entire period of one month before pregnancy through the end of the first 
trimester. Exposure was more likely among those with a higher education and of non-
Hispanic white race-ethnicity. These mothers also more frequently reported any folic acid 
use from one month preconception through the first month of pregnancy (Table 1). Of the 
exposed mothers, only 24% had EDDs during 1997–2002; the remaining 76% of exposed 
mothers had EDDs from 2003–2007 (Table 1).
We assessed 24 groups of birth defects that had 400 or more case infants. One group, 
esophageal atresia (n=499), had no mothers exposed to venlafaxine, and six groups had 2 or 
fewer mothers exposed: anotia/microtia, d-transposition of the great arteries, tetralogy of 
Fallot, hypoplastic left heart syndrome, anorectal atresia, and diaphragmatic hernia. ORs 
were not assessed for these seven defects (Table 2). We observed all effect estimates to be 
elevated, but select groups had statistically significantly elevated ORs: anencephaly; septal 
heart defects, likely driven by the association with the subcategory atrial septal defect 
secundum (ASD) or ASD not otherwise specified; left ventricular outflow tract obstruction 
(LVOTO) defects, likely driven by the association with the subcategory coarctation of the 
aorta; cleft palate; and gastroschisis (Table 2).
When restricting analysis to isolated birth defects, the majority of associations remained 
statistically significant, although differences were observed for some groups. Effect 
estimates for some associations, including anencephaly, cleft palate alone, and gastroschisis, 
increased slightly (cOR: 6.2; 95% CI: 1.5–20.0; cOR: 4.4; 95% CI: 1.5–11.6; and cOR: 4.2; 
95% CI: 1.3–11.7, respectively). The association with LVOTO defects decreased (cOR: 3.1; 
95% CI: 1.1–8.3), likely because the association with subcategory coarctation of the aorta 
was no longer statistically significant (cOR: 3.5; 95% CI: 0.8–11.1).
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In our post-hoc analyses restricting the data to EDDs in the most recent 5-year time period, 
effect estimates remained elevated; however, most were no longer statistically significant. 
The associations with anencephaly and LVOTO defects remained statistically significantly 
elevated, while the associations with cleft palate and gastroschisis were of borderline 
significance (Table 3).
In our post-hoc evaluation of other medications or illnesses during pregnancy, we did not 
observe any patterns among venlafaxine-exposed mothers. Two exposed case mothers 
(2.6%) were also exposed to high blood pressure medications, seven exposed case mothers 
(9.0%) were exposed to antiepileptic medications (not valproic acid), and two exposed case 
mothers (2.6%) reported opioid analgesic medications. Among these mothers exposed to 
multiple medications, no patterns of medications or of birth defects were observed. For 
example, three of the case mothers exposed to venlafaxine were also exposed to 
clonazepam, an antiepileptic medication, but each of their infants had a different condition: 
cleft palate, an association of heart defects—ASD and ventricular septal defect, and 
tetralogy of Fallot. In the open-ended questions about general illness during pregnancy, 
responses varied; however, no pattern of other illness was observed among venlafaxine-
exposed mothers (data not shown).
In our post-hoc analysis exploring recall bias, we re-assessed the crude associations 
assuming under-reporting among control mothers. If we assumed 30% of exposed control 
mothers did not report exposure, all associations remained elevated, although closer to the 
null. For example, the association with anencephaly decreased to 3.9 (95% CI: 1.1–11.8). In 
this hypothetical scenario, the association with coarctation of the aorta decreased to 3.1 
(95% CI: 1.0–8.1), and the association with cleft palate alone decreased to 2.5 (95% CI: 0.9–
6.1).
Discussion
Using data from the NBDPS, a multi-site, population-based case-control study in the United 
States, we observed that periconceptional venlafaxine exposure might be associated with 
certain birth defects, specifically anencephaly, cleft palate, gastroschisis, and some heart 
defects, such as ASD secundum or ASD not otherwise specified and coarctation of the aorta. 
However, because these analyses were based on a small number of exposed cases, many of 
the estimates were imprecise with wide confidence intervals.
Reported exposure to venlafaxine during early pregnancy increased among all mothers over 
time. This corroborates previous studies that have shown an increase in antidepressant use in 
the United States over time (Harman and others, 2009; Marcus and Olfson, 2010; Olfson 
and Marcus, 2009), including use among pregnant women (Alwan and others, 2011; 
Andrade and others, 2008; Cooper and others, 2007).
Our findings differed from earlier studies. One prospective cohort study by Einarson and 
colleagues enrolled pregnant women via seven pregnancy counseling centers. The authors 
compared venlafaxine-exposed women to women exposed to SSRIs and women exposed to 
medications believed to be non-teratogenic during pregnancy. Two of the exposed babies 
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had a major malformation; however, no significant differences were found between the three 
groups. This study consisted of a small number of subjects, which limited its ability to 
examine associations with rare outcomes (Einarson et al., 2001). Oberlander and colleagues 
used linked administrative health data and prescription information to determine venlafaxine 
exposure during the first trimester. They found no increased risk of birth defects overall or 
for cardiovascular defects compared to women unexposed to SSRIs, other SNRIs, and 
benzodiazepines (Oberlander et al., 2008). Of the limited information from animal studies, 
one study reported that venlafaxine use during pregnancy had adverse effects on rat fetuses 
(da-Silva and others, 1999), but studies on rats and rabbits performed by the manufacturer 
found no teratogenic effects (2007).
Biologically, venlafaxine functions in the nervous system by blocking the reuptake of two 
neurotransmitters, serotonin and norepinephrine, at the synaptic junction (2007). During 
embryogenesis, these neurotransmitters are expressed in early phases, potentially playing a 
role as early as gastrulation (Lauder, 1988). It is believed that these neurotransmitters may 
act as morphogens, signaling molecules that have a dose-dependent function on receptive 
cells (Buznikov and others, 2001; Lauder, 1988). Several animal studies have provided 
specific evidence for serotonin acting as a morphogen in craniofacial and cardiac 
development (Choi and others, 1997; Cote and others, 2007; Moiseiwitsch, 2000; 
Moiseiwitsch and Lauder, 1995; Nebigil and others, 2000; Nebigil and Maroteaux, 2001). 
Studies have also shown that norepinephrine influences neural crest cell formation and 
differentiation during embryogenesis (Hu and others, 2009; Ren and others, 2001; Ren and 
others, 2003; Sieber-Blum and Ren, 2000; Zhang and others, 1997). Thus, if venlafaxine is 
taken during early pregnancy and interferes with these embryologic signaling pathways, it is 
plausible that venlafaxine could affect craniofacial and cardiac development. This is 
consistent with our findings of associations with septal heart defects, LVOTO defects and 
cleft palate.
Another potential explanation for the associations observed is that women who use 
venlafaxine have underlying differences compared to non-users. Some differences in 
demographic and lifestyle factors between exposed and exposed mothers were noted. For 
example, exposure was more common among non-Hispanic white mothers and folic acid 
users. However, no differences were observed between venlafaxine-exposed and unexposed 
mothers in terms of potential risk factors such as exposure to cigarette smoking or alcohol 
consumption during early pregnancy. We also looked at exposure to other medications that 
might increase the risk for birth defects; however, no patterns were observed.
Because venlafaxine is a second-line treatment that is prescribed to individuals that do not 
respond well to first-line treatments like SSRIs (Schueler and others, 2011), it is possible 
that women treated with venlafaxine have more severe disease or underlying differences in 
their depression, which might account for the associations we observed. Depression, itself, 
has been shown to be associated with a number of adverse pregnancy outcomes, such as 
spontaneous abortion, fetal death, low birth weight, and preterm birth (Bonari and others, 
2004; Grote and others, 2010). In our study, over 50% of venlafaxine-exposed mothers 
reported using the medication during the entire early pregnancy period, which suggests long-
term treatment. Although we ask questions in the maternal interview about maternal disease, 
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we do not have specific questions about depression, so we are unable to assess confounding 
by indication.
Given that the maternal interview took place after the birth outcome is known and that we 
found all effect estimates to be elevated, we were concerned about recall bias. In our post-
hoc analysis examining the potential role of under-reporting among control mothers, effect 
estimates remained elevated, although were closer to the null, suggesting that our observed 
results were unlikely the result of significant recall bias. Our assumption that 30% of 
exposed control mothers did not report exposure is likely too high; the magnitude of under-
reporting is probably smaller. Previous studies have shown that recall bias might not have as 
considerable an effect in practice as one might expect (Drews and others, 1990; Khoury and 
others, 1994; Mackenzie and Lippman, 1989; Zierler and Rothman, 1985). In the NBDPS, 
we study a number of different medications, including antidepressant exposures, and 
previous NBDPS studies have not observed a broad increase in the number of elevated 
associations with birth defects. Thus, it is not likely that recall bias would play a major role 
for venlafaxine, but not other NBDPS exposures (Alwan and others, 2010; Alwan and 
others, 2007). Additionally, it has been shown that asking about medications in relation to 
treating illness as well as asking directly about specific medications can improve postnatal 
recall (Mitchell and others, 1986). Both techniques are utilized in the NBDPS interview, but 
venlafaxine was not included in the list of specific medications listed until 2006; however, 
first line medications for depression (e.g., paroxetine, fluoxetine, sertraline) have always 
been included, probably prodding the report of other antidepressants as well. Differential 
reporting of exposure between case and control mothers might occur because of differences 
in the timing of the interview after birth. However, average time to interview is relatively 
similar for both case and control mothers—about 11 months for case mothers and about 9 
months for control mothers.
Our analysis should be interpreted in light of several additional limitations. In the maternal 
interview, mothers are asked about the frequency of medication use but not the dose, which 
could affect dose-response relationships. Since the mothers are asked to recall pregnancy 
exposures and the information collected during the interview was not validated, 
misclassification of exposures is possible. Since venlafaxine was not specifically asked 
about in the maternal interview until 2006, it is possible the medication was under-reported 
during the earlier time period. Because we conducted a large number of tests, some of the 
associations may be due to chance. We examined associations with 24 groups of birth 
defects at the 0.05 significance level, so we would expect at least 1 positive result to occur 
by chance. It is possible that by selecting groups of birth defects with at least 400 cases, we 
inadvertently selected for those with elevated risk point estimates. Another potential 
limitation to consider is that NBDPS study centers may have under-ascertained cases that 
were prenatally diagnosed and terminated. This would most likely affect birth defects with 
higher proportions of terminations (e.g., anencephaly, spina bifida, or omphalocele), and this 
potential under-ascertainment might have biased the results for these birth defect outcomes 
(Waller and others, 2000). Lastly, the NBDPS had a non-participation rate of about 30%; 
however, it is unlikely that participation would differ between cases and controls based on 
whether or not the woman used venlafaxine. A previous analysis that investigated selection 
bias in the NBDPS determined that, although there were some small statistically significant 
Polen et al. Page 8













differences in some demographic characteristics, the NBDPS control population is generally 
representative of the base population (Cogswell and others, 2009).
Strengths of our study include the fact that our data come from a large, population-based, 
case-control study, which allowed us to look at a large number of birth defect groups and the 
ability to examine venlafaxine exposure separate from other antidepressant medications. All 
the defects included have consistent case definitions, and the cases in the study are classified 
by clinical experts in genetics and pediatric cardiology.
In conclusion, our data suggest that maternal periconceptional use of venlafaxine might be 
associated with certain birth defects, specifically anencephaly, cleft palate, gastroschisis, and 
some heart defects, such as ASD secundum or ASD not otherwise specified and coarctation 
of the aorta. However, our analyses are based on a small number of mothers exposed to 
venlafaxine during early pregnancy, which led to imprecise estimates with wide confidence 
intervals. Additional studies are needed to confirm these results.
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Flow diagram showing study participation rates and exclusion criteria for mothers of case 
and control infants in the analyses of venlafaxine and birth defects, National Birth Defects 
Prevention Study, 1997–2007
Polen et al. Page 13













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Polen et al. Page 17
Table 2
Association between use of venlafaxine just before and during early pregnancy and the occurrence of certain 
birth defects, National Birth Defects Prevention Study, 1997–2007




No Major Birth Defects (Control Infants) 8002 14 1.0 (ref) 1.0 (ref)
Anencephaly 411 4 5.6 (1.3–18.0) 6.3 (1.5–20.2)
SpinaBifida 874 3 2.0 (0.4–7.1) 2.1 (0.4–7.6)
Anotia or Microtia 470 1 § §
Conotruncal Heart Defects 1754 6 2.0 (0.6–5.4) 1.9 (0.6–5.3)
D-Transposition of the Great Arteries 545 2 § §
Tetralogy of Fallot 799 1 § §
Septal Heart Defects 3621 18 2.9 (1.3–6.2) 3.0 (1.4–6.4)
Perimembranous Ventricular Septal Defect 1410 6 2.4 (0.8–6.8) 2.4 (0.8–6.7)
Atrial Septal Defect, type 2 or not otherwise specified 2181 11 2.9 (1.2–6.9) 3.1 (1.3–7.4)
Ventricular Septal Defect-Atrial Septal Defect Association 576 3 3.0 (0.5–10.8) 3.1 (0.6–11.3)
Right Ventricular Outflow Tract Obstruction Defects2 1250 5 2.3 (0.6–6.7) 2.3 (0.6–6.6)
Pulmonary Valve Stenosis 985 5 2.7 (0.8–8.1) 2.7 (0.8–7.9)
Left Ventricular Outflow Tract Obstruction Defects 1444 9 3.6 (1.4–8.9) 3.3 (1.2–8.2)
Hypoplastic Left Heart Syndrome 425 2 § §
Coarctation of the Aorta 768 6 4.5 (1.4–12.5) 4.1 (1.3–11.5)
Cleft Lip with or without Cleft Palate 2134 6 1.6 (0.5–4.4) 1.5 (0.5–4.3)
Cleft Palate alone 1123 7 3.5 (1.2–9.3) 3.3 (1.1–8.8)
AnorectalAtresia 741 1 § §
Esophageal Atresia 499 0 § §
Hypospadias, 2nd/3rd degree3 1571 7 2.6 (0.8–8.7) 2.3 (0.7–7.9)
Any Limb Reduction Defect 847 3 2.0 (0.4–7.3) 2.1 (0.4–7.6)
Craniosynostosis 982 3 1.7 (0.3–6.3) 1.5 (0.3–5.4)
Diaphragmatic Hernia 594 2 § §
Gastroschisis 911 6 3.8 (1.2–10.5) 5.7 (1.8–15.9)4
§
Two or fewer exposed cases; No odds ratios calculated.
1




Hypospadias among male infants only; 4063 control male infants
4
Association with gastroschisis adjusted for age (<20, ≥20 years) and race (NH White, Other)
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Table 3
Association between use of venlafaxine just before and during early pregnancy and the occurrence of certain 
birth defects, National Birth Defects Prevention Study, Restricted to 2003–2007
Birth Defects Total Exposed Crude Odds Ratio
(Exact 95% CI)
No Major Birth Defects (Control Infants) 4038 12 1.0 (ref)
Anencephaly 210 4 6.5 (1.5–21.7)
SpinaBifida 431 2 §
Anotia or Microtia 216 1 §
Contruncal Heart Defects 826 3 1.2 (0.2–4.5)
D-Transposition of the Great Arteries 254 2 §
Tetralogy of Fallot 388 0 §
Septal Heart Defects 1795 11 2.1 (0.8–5.1)
Perimembranous Ventricular Septal Defect 659 4 2.0 (0.5–6.8)
Atrial Septal Defect type 2 or not otherwise specified 1221 6 1.7 (0.5–4.8)
Ventricular Septal Defect-Atrial Septal Defect Association 308 1 §
Right Ventricular Outflow Tract Obstruction Defects1 669 3 1.5 (0.3–5.6)
Pulmonary Valve Stenosis 543 3 1.9 (0.3–6.9)
Left Ventricular Outflow Tract Obstruction Defects 790 7 3.0 (1.0–8.3)
Hypoplastic Left Heart Syndrome 220 2 §
Coarctation of the Aorta 427 4 3.2 (0.7–10.5)
Cleft Lip with or without Cleft Palate 1036 5 1.6 (0.4–4.8)
Cleft Palate alone 522 5 3.1 (0.9–9.6)
AnorectalAtresia 344 1 §
Esophageal Atresia 215 0 §
Hypospadias, 2nd/3rd degree2 777 6 3.2 (0.8–13.5)
Any Limb Reduction Defect 385 3 2.6 (0.5–9.8)
Craniosynostosis 574 2 §
Diaphragmatic Hernia 305 1 §
Gastroschisis 508 5 3.3 (0.9–10.2)
§




Hypospadias among male infants only; 2089control male infants
Birth Defects Res A Clin Mol Teratol. Author manuscript; available in PMC 2015 June 29.
